Clincosm LogoSign in Get a demo

DDI Study of Orelabrutinib

Sponsor
Beijing InnoCare Pharma Tech Co., Ltd. (Industry)
Overall Status
Completed
CT.gov ID
NCT05316857
Collaborator
(none)
36
Enrollment
1
Location
2
Arms
5.9
Actual Duration (Months)
6.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a phase I, single-center, open-label, fixed-sequence clinical study. The primary objective was to evaluate the effects of multiple administrations of rifampin or itraconazole on the pharmacokinetic characteristics of a single administration of orelabrutinib tablets in healthy Chinese subjects. The secondary objective was to evaluate the safety and tolerability of rifampicin or itraconazole combined with orelabrutinib tablets in healthy Chinese subjects.

Condition or Disease Intervention/Treatment Phase
  • Drug: Orelabrutinib + Rifampin
  • Drug: Orelabrutinib + Itraconazole
 Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
A Phase I, Single-center, Open-label, Fixed-sequence Clinical Study to Evaluate the Effects of Multiple Administrations of Rifampin or Itraconazole on the Pharmacokinetic Characteristics of a Single Administration of Orelabrutinib Tablets in Healthy Subjects
Actual Study Start Date :
Dec 16, 2021
Actual Primary Completion Date :
Jan 4, 2022
Actual Study Completion Date :
Jun 13, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Orelabrutinib + Rifampin

Orelabrutinib is a white, round, uncoated table,Subjects take high dose orelabrutinib in the first day and the tenth day. Rifampin is a capsule,Subjects take 600mg QD rifampin in the third day to the eleventh.

Drug: Orelabrutinib + Rifampin
Orelabrutinib + Rifampin
Other: Orelabrutinib + Itraconazole

Orelabrutinib is a white, round, uncoated table,Subjects take low dose orelabrutinib in the first day and the eighth day. Itraconazole is a capsule,Subjects take 600mg QD rifampin in the third day to the tenth.

Drug: Orelabrutinib + Itraconazole
Orelabrutinib + Itraconazole

Outcome Measures

Primary Outcome Measures

  1. Cmax [up to 3 months]

    To preliminarily obtain pharmacokinetic (PK) data of Orelabrutinib in the treatment of advanced solid tumors include the peak plasma concentration (Cmax)

Secondary Outcome Measures

  1. Tmax [up to 3 months]

    To preliminarily obtain pharmacokinetic (PK) data of Orelabrutinib in the treatment of advanced solid tumors include Time to Maximum Plasma Concentration(Tmax)

  2. Incidence of Treatment-Emergent Adverse Events [up to 3 months]

    To evaluate the safety and tolerability of Orelabrutinib

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  1. Subject who can fully understand the objectives, nature, methods and possible adverse reactions of the trial, and volunteers to be the subject, and has signed an informed consent form before the start of any study procedure, and guarantees that any procedure will be participated in by himself/herself;

  2. Male or female subjects aged between 18 and 45 years old (inclusive) at the time of screening;

  3. Body weight ≥50 kg for male subjects, ≥45 kg for female subjects, and a body mass index (BMI) of 19 to 26.0 kg/m2 (inclusive);

  4. Be able to communicate well with investigator, and understand and comply with the requirements of this study.

Exclusion Criteria:

  1. Complete physical examination, routine laboratory tests, cardiac color ultrasound and other examinations are abnormal with clinical significance;

  2. Hepatitis B surface antigen or E antigen, hepatitis C antibody, human immunodeficiency virus (HIV) antibody, or syphilis antibody are positive;

  3. C-reactive protein for novel coronavirus screening is abnormal with clinical significance, or the novel coronavirus nucleic acid testing is positive;

  4. Have received any drugs and therapy which are in the study protocol within 1 month before screening

  5. Have taken prescription drugs, over-the-counter drugs, dietary supplements, or Chinese herbal medicine within 14 days before the first administration of the investigational drug

  6. Have any history of clinically serious diseases, or diseases or conditions that the investigator believes may affect the results of the study.

  7. Subject who has a childbirth plan during the study period and within 3 months after the end of the study, or the subject and his/her partner do not agree to take strict contraceptive measures during this period;

  8. Other subjects judged by the investigator as unsuitable to participate in this study NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The First Affiliated Hospital of Soochow University Suzhou Jiangsu China 215000

Sponsors and Collaborators

  • Beijing InnoCare Pharma Tech Co., Ltd.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Beijing InnoCare Pharma Tech Co., Ltd.
ClinicalTrials.gov Identifier:
NCT05316857
Other Study ID Numbers:
  • ICP-CL-00117
First Posted:
Apr 7, 2022
Last Update Posted:
Jul 6, 2022
Last Verified:
Jun 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Itraconazole
Rifampin

Study Results

No Results Posted as of Jul 6, 2022